

Citations

1. Iron deficiency—United States, 1999-2000. *MMWR Morb Mortal Wkly Rep* 2002;51:897-899.
2. Brownlie T, Utermohlen V, Hinton PS et al. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. *Am J Clin Nutr* 2002;75:734-742.
3. Puig S, Askeland E, Thiele DJ. Coordinated remodeling of cellular metabolism during iron deficiency through targeted mRNA degradation. *Cell* 2005;120:99-110.
4. Yip R, Dallman PR. Iron. In: Ziegler EE, Filer LJ, eds. *Present Knowledge in Nutrition*. 7th ed. Washington, DC: ILSI Press; 1996:277-292.
5. Lee GR. Disorders of iron metabolism and heme synthesis. In: Lee GR, Foerster J, Paraskevas F et al, eds. *Wintrobe's Clinical Hematology*. 10th ed. Baltimore: Williams & Wilkins; 1999:979-1070.
6. Zlotkin S, Arthur P, Antwi KY, Yeung G. Treatment of anemia with microencapsulated ferrous fumarate plus ascorbic acid supplied as sprinkles to complementary (weaning) foods. *Am J Clin Nutr* 2001;74:791-795.
7. Cogswell ME, Parvanta I, Ickes L et al. Iron supplementation during pregnancy, anemia, and birth weight: a randomized controlled trial. *Am J Clin Nutr* 2003;78:773-781.
8. Lozoff B, De Andraca I, Castillo M et al. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. *Pediatrics* 2003;112:846-854.
9. Mills KC, Curry SC. Acute iron poisoning. *Emerg Med Clin North Am* 1994;12:397-413.
10. Baillie FJ, Morrison AE, Fergus I. Soluble transferrin receptor: a discriminating assay for iron deficiency. *Clin Lab Haematol* 2003;25:353-357.
11. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. *Clin Chim Acta* 2003;329:9-22.
12. Mei Z, Parvanta I, Cogswell ME et al. Erythrocyte protoporphyrin or hemoglobin: which is a better screening test for iron deficiency in children and women? *Am J Clin Nutr* 2003;77:1229-1233.
13. Morris CC. Pediatric iron poisonings in the United States. *South Med J* 2000;93:352-358.
14. Mainous AG 3rd, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. *Ann Fam Med* 2004;2:133-138.
15. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 1996;13:399-408.
16. Anderson GJ, Powell LW. Of metals, mice, and men: what animal models can teach us about body iron loading. *J Clin Invest* 2000;105:1185-1186.
17. Walker AR, Segal I. Iron overload in Sub-Saharan Africa: to what extent is it a public health problem? *Br J Nutr* 1999;81:427-434.
18. Sazawal S, Black RE, Ramsan M et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. *Lancet* 2006;367:133-152.
19. Makrides M, Crowther CA, Gibson RA et al. Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial. *Am J Clin Nutr* 2003;78:145-153.
20. Roob JM, Khoschsorur G, Tiran A et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. *J Am Soc Nephrol* 2000;11:539-549.
21. Druke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. *Circulation* 2002;106:2212-2217.
22. Day SM, Duquaine D, Mundada LV et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. *Circulation* 2003;107:2601-2606.
23. Klipstein-Grobusch K, Grobbee DE, den Breeijen JH et al. Dietary iron and risk of myocardial infarction in the Rotterdam Study. *Am J Epidemiol* 1999;149:421-428.
24. Weinberg ED. Iron withholding: a defense against infection and neoplasia. *Physiol Rev* 1984;64:65-102.
25. Cutler P. Deferoxamine therapy in high-ferritin diabetes. *Diabetes* 1989;38:1207-1210.
26. Salonen JT, Nyyssönen K, Korpela H et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. *Circulation* 1992;86:803-811.
27. Oh VM. Iron dextran and systemic lupus erythematosus. *BMJ* 1992;305:1000.
28. Dabbagh AJ, Trenam CW, Morris CJ, Blake DR. Iron in joint inflammation. *Ann Rheum Dis* 1993;52:67-73.
29. Ascherio A, Willett WC, Rimm EB et al. Dietary iron intake and risk of coronary disease among men. *Circulation* 1994;89:969-974.
30. Stevens RG, Graubard BI, Micozzi MS et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. *Int J Cancer* 1994;56:364-369.

Citations and Reference Literature: Iron

31. Wurzelmann JJ, Silver A, Schreinemachers DM et al. Iron intake and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 1996;5:503-507.
32. Kiechl S, Willeit J, Egger G et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. *Circulation* 1997;96:3300-3307.
33. Tzonou A, Laggiou P, Trichopoulou A et al. Dietary iron and coronary heart disease risk: a study from Greece. *Am J Epidemiol* 1998;147:161-166.
34. De Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. *Arch Intern Med* 1999;159:1542-1548.
35. Bartzokis G, Cummings J, Perlman S et al. Increased basal ganglia iron levels in Huntington disease. *Arch Neurol* 1999;56:569-574.
36. Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. *Circulation* 1999;99:852-854.
37. Kato I, Dnistrian AM, Schwartz M et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. *Int J Cancer* 1999;80:693-698.
38. Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. *Cell Mol Biol (Noisy-le-grand)* 2000;46:761-776.
39. Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. *Cell Mol Biol (Noisy-le-grand)* 2000;46:731-741.
40. Gangaidzo IT, Moyo VM, Mvundura E et al. Association of pulmonary tuberculosis with increased dietary iron. *J Infect Dis* 2001;184:936-939.
41. Van Langendonck A, Casanas-Roux F, Donnez J. Iron overload in the peritoneal cavity of women with pelvic endometriosis. *Fertil Steril* 2002;78:712-718.
42. Powers KM, Smith-Weller T, Franklin GM et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. *Neurology* 2003;60:1761-1766.
43. Lee DH, Anderson KE, Harnack LJ et al. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. *J Natl Cancer Inst* 2004;96:403-407.
44. Jiang R, Manson JE, Meigs JB et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. *JAMA* 2004;291:711-717.
45. Gotz ME, Double K, Gerlach M et al. The relevance of iron in the pathogenesis of Parkinson's disease. *Ann N Y Acad Sci* 2004;1012:193-208.
46. Zecca L, Youdim MB, Riederer P et al. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci* 2004;5:863-873.
47. Leonards JR, Levy G, Niemczura R. Gastrointestinal blood loss during prolonged aspirin administration. *N Engl J Med* 1973;289:1020-1022.
48. Palme G, Koeppe P. [Comparative experimental studies in animals and humans on gastrointestinal blood loss following antirheumatic pharmacotherapy] (author's translation). *Arzneimittelforschung* 1978;28:426-428.
49. Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. *Br J Clin Pharmacol* 1991;31:251-255.
- 49a. Schaefer JP, Tam Y, Hasinoff BB, et al. Ferrous sulphate interacts with captopril. *Br J Clin Pharmacol* 1998;46(4):377-381
50. Lee SC, Park SW, Kim DK et al. Iron supplementation inhibits cough associated with ACE inhibitors. *Hypertension* 2001;38:166-170.
51. Wong KC, Woo KS, Lam WK et al. A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients. *Int J Artif Organs* 1995;18:757-762.
52. Ozbek N, Ozen S, Saatci U. Enalapril-induced anemia in a renal transplant patient. *Acta Paediatr Jpn* 1997;39:626-627.
53. Incalzi RA, Gemma A, Carbonin P. ACE inhibitors: a possible cause of unexplained anemia. *J Am Geriatr Soc* 1998;46:117-118.
54. Albitar S, Genin R, Fen-Chong M et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. *Nephrol Dial Transplant* 1998;13:1206-1210.
55. Gossman J, Thurmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. *Kidney Int* 1996;50:973-978.
56. Rolla G, Bucca C, Brussino L. Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor. *J Allergy Clin Immunol* 1994;93:1074-1075.
57. Coste JF, DeBari VA, Keil LB, Needle MA. In-vitro interactions of oral hematinics and antacid suspensions. *Curr Ther Res* 1977;22:205-215.
58. Benjamin BI, Cortell S, Conrad ME. Bicarbonate-induced iron complexes and iron absorption: one effect of pancreatic secretions. *Gastroenterology* 1967;35:389-396.
59. Hall GJ, Davis AE. Inhibition of iron absorption by magnesium trisilicate. *Med J Aust* 1969;2:95-96.

Citations and Reference Literature: Iron

60. Aymard JP, Aymard B, Netter P et al. Haematological adverse effects of histamine H₂-receptor antagonists. *Med Toxicol Adverse Drug Exp* 1988;3:430-448.
61. Campbell NR, Hasinoff BB, Meddings JB et al. Ferrous sulfate reduces cimetidine absorption. *Dig Dis Sci* 1993;38:950-954.
62. Conrad ME, Schade SG. Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile. *Gastroenterology* 1968;55:35-45.
63. Hathcock JN. Metabolic mechanisms of drug-nutrient interactions. *Fed Proc* 1985;44:124-129.
64. D'Arcy PF, McElnay JC. Drug interactions in the gut involving metal ions. *Rev Drug Metab Drug Interact* 1985;5:83-112.
65. Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. *Adv Exp Med Biol* 1989;249:173-184.
66. Sturniolo GC, Montino MC, Rossetto L et al. Inhibition of gastric acid secretion reduces zinc absorption in man. *J Am Coll Nutr* 1991;10:372-375.
67. Lambat Z, Limson JL, Daya S. Cimetidine: antioxidant and metal-binding properties. *J Pharm Pharmacol* 2002;54:1681-1686.
68. Rastogi SP, Padilla F, Boyd CM. Effect of aluminum hydroxide on iron absorption. *J Ark Med Soc* 1976;73:133-134.
69. Ekenved G, Halvorsen L, Solvell L. Influence of a liquid antacid on the absorption of different iron salts. *Scand J Haematol Suppl* 1976;28:65-77.
70. O'Neil-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. *JAMA* 1986;255:1468-1470.
71. Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. *Ann Emerg Med* 1999;33:400-405.
72. Wallace KL, Curry SC, LoVecchio F, Raschke RA. Effect of magnesium hydroxide on iron absorption after ferrous sulfate. *Ann Emerg Med* 1999;34:685-687.
73. Macdougall BR, Bailey RJ, Williams R. H₂-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure: two controlled trials. *Lancet* 1977;1:617-619.
74. Bianchi FM, Cavassini GB, Leo P. Iron protein succinylate in the treatment of iron deficiency: potential interaction with H₂-receptor antagonists. *Int J Clin Pharmacol Ther Toxicol* 1993;31:209-217.
75. Partlow ES, Chan SC, Pap KM et al. The effect of ferrous sulfate on famotidine serum levels in healthy patients. *Clin Invest Med* 1994;17:B15.
76. Partlow ES, Campbell NR, Chan SC et al. Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. *Clin Pharmacol Ther* 1996;59:389-393.
77. Stockley IH. *Drug Interactions*. 6th ed. London: Pharmaceutical Press; 2002.
78. Esposito R. Cimetidine and iron-deficiency anaemia. *Lancet* 1977;2:1132.
79. Rosner F. Cimetidine and iron absorption. *Lancet* 1978;1:95.
80. Drasar BS, Shiner M, McLeod GM. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. *Gastroenterology* 1969;56:71-79.
81. Drasar BS, Shiner M. Studies on the intestinal flora. II. Bacterial flora of the small intestine in patients with gastrointestinal disorders. *Gut* 1969;10:812-819.
82. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections: a perspective. *Ann Intern Med* 1973;78:271-276.
83. Walker WA, Isselbacher KJ. Uptake and transport of macromolecules by the intestine: possible role in clinical disorders. *Gastroenterology* 1974;67:531-550.
84. Mayron LW. Portals of entry—a review. *Ann Allergy* 1978;40:399-405.
85. Russell RM, Krasinski SD, Samloff IM. Correction of impaired folic acid (Pte Glu) absorption by orally administered HCl in subjects with gastric atrophy. *Am J Clin Nutr* 1984;39:656.
86. Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004;292:1955-1960.
87. Leonard JP, Desager JP, Beckers C, Harvenge C. In vitro binding of various biological substances by two hypocholesterolaemic resins: cholestyramine and colestipol. *Arzneimittelforschung* 1979;29:979-981.
88. Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. *Dig Dis Sci* 1985;30:477-482.
89. Torkos S. Drug-nutrient interactions: a focus on cholesterol-lowering agents. *Int J Integr Med* 2000;2:9-13.
90. Thomas FB, McCullough FS, Greenberger NJ. Inhibition of the intestinal absorption of inorganic and hemoglobin iron by cholestyramine. *J Lab Clin Med* 1971;78:70-80.

Citations and Reference Literature: Iron

91. Thomas FB, Salsburey D, Greenberger NJ. Inhibition of iron absorption by cholestyramine: demonstration of diminished iron stores following prolonged administration. *Am J Dig Dis* 1972;17:263-269.
92. Schlierf G, Vogel G, Kohlmeier M et al. [Long-term therapy of familial hypercholesterolemia in young patients with colestipol: availability of minerals and vitamins]. *Klin Wochenschr* 1985;63:802-806.
93. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. *J Bone Miner Res* 1999;14 Suppl 2:53-65.
94. Fleisch H. Bisphosphonates: mechanisms of action. *Endocr Rev* 1998;19:80-100.
95. Campbell NR, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. *Clin Pharmacol Ther* 1989;45:220-225.
96. Greene RJ, Hall AD, Hider RC. The interaction of orally administered iron with levodopa and methyldopa therapy. *J Pharm Pharmacol* 1990;42:502-504.
97. Campbell NR, Rankine D, Goodridge AE et al. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. *Br J Clin Pharmacol* 1990;30:599-605.
98. Campbell RR, Hasinoff B, Chernenko G et al. The effect of ferrous sulfate and pH on L-dopa absorption. *Can J Physiol Pharmacol* 1990;68:603-607.
99. Zhou B, Westaway SK, Levinson B et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. *Nat Genet* 2001;28:345-349.
100. Bharath S, Hsu M, Kaur D et al. Glutathione, iron and Parkinson's disease. *Biochem Pharmacol* 2002;64:1037-1048.
101. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. *Ann NY Acad Sci* 2004;1012:306-325.
102. Shachar DB, Kahana N, Kampel V et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. *Neuropharmacology* 2004;46:254-263.
103. Ueno K, Tanaka K, Tsujimura K et al. Impairment of cefdinir absorption by iron ion. *Clin Pharmacol Ther* 1993;54:473-475.
104. Cefdinir—a new oral cephalosporin. *Med Lett Drugs Ther* 1998;40:85-87.
105. Kato R, Ooi K, Takeda K et al. Lack of interaction between cefdinir and calcium polycarbophil: in vitro and in vivo studies. *Drug Metab Pharmacokinet* 2002;17:363-366.
106. Rigdon RH, Crass G, Martin N. Anemia produced by chloramphenicol (chloromycetin) in the duck. *AMA Arch Pathol* 1954;58:85-93.
107. Saidi P, Wallerstein RO, Aggeler PM. Effect of chloramphenicol on erythropoiesis. *J Lab Clin Med* 1961;57:247-256.
108. McCurdy PR. Chloramphenicol bone marrow toxicity. *JAMA* 1961;176:588-593.
109. Jiji RM, Gangarosa EJ, de la Macorra F. Chloramphenicol and its sulfamoyl analogue: report of reversible erythropoietic toxicity in healthy volunteers. *Arch Intern Med* 1963;111:116-128.
110. Scott JL, Finegold SM, Belkin GA, Lawrence JS. A controlled double-blind study of the hematologic toxicity of chloramphenicol. *N Engl J Med* 1965;272:1137-1142.
111. Warner RR, Myers MC, Burns J, Mitra S. Analytical electron microscopy of chlorhexidine-induced tooth stain in humans: direct evidence for metal-induced stain. *J Periodont Res* 1993;28:255-265.
112. Powanda MC, Blackburn BS, Bostian KA et al. Clofibrate-induced alterations in zinc, iron and copper metabolism. *Biochem Pharmacol* 1978;27:125-127.
113. Hettiarachchi M, Hilmers DC, Liyanage C, Abrams SA. Na2EDTA enhances the absorption of iron and zinc from fortified rice flour in Sri Lankan children. *J Nutr* 2004;134:3031-3036.
114. Davidsson L, Ziegler E, Zeder C et al. Sodium iron EDTA [NaFe(III)EDTA] as a food fortificant: erythrocyte incorporation of iron and apparent absorption of zinc, copper, calcium, and magnesium from a complementary food based on wheat and soy in healthy infants. *Am J Clin Nutr* 2005;81:104-109.
115. Aapro M, San Miguel J. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta. *Oncology* 2004;67 Suppl 1:17-22.
116. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. *Haematologica* 2002;87:1209-1221.
117. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. *J Clin Oncol* 2002;20:4083-4107.
118. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? *Oncologist* 1998;3:275-278.
119. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. *Clin Nephrol* 1997;48:34-40.

Citations and Reference Literature: Iron

120. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. *Kidney Int* 2003;63:217-224.
121. Kooistra MP, Niemantsverdriet EC, van Es A et al. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. *Nephrol Dial Transplant* 1998;13:82-88.
122. Auerbach M, Winchester J, Wahab A et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. *Am J Kidney Dis* 1998;31:81-86.
123. Vankova S, Safarova R, Horackova M et al. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis]. *Cas Lek Cesk* 2001;140:209-213.
124. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. *Clin Nephrol* 2002;57:136-141.
125. Nissenson AR, Berns JS, Sakiewicz P et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. *Am J Kidney Dis* 2003;42:325-330.
126. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. *J Clin Oncol* 2004;22:1301-1307.
127. Pedrazzoli P, Tullio C, Cerea G, Siena S. Iron supplement in cancer patients receiving erythropoietin. *J Clin Oncol* 2004;22:4428; author reply 4428-4429.
128. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet* 2003;362:1255-1260.
129. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. *J Clin Invest* 2004;113:1251-1253.
130. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest* 2004;113:1271-1276.
131. Arndt U, Kaltwasser JP, Gottschalk R et al. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. *Ann Hematol* 2005;84(3):159-166.
132. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. *Blood* 2000;96:823-833.
133. Polk RE, Healy DP, Sahai J et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. *Antimicrob Agents Chemother* 1989;33:1841-1844.
134. Okhamafe AO, Akerele JO, Chukuka CS. Pharmacokinetic interactions of norfloxacin with some metallic agents. *Int J Pharmaceutics* 1991;68:11-16.
135. Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. *Br J Clin Pharmacol* 1991;31:257-261.
136. Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. *J Antimicrob Chemother* 1991;28:87-94.
137. Brouwers JR. Drug interactions with quinolone antibacterials. *Drug Saf* 1992;7:268-281.
138. Lehto P, Kivistö KT, Neuvonen PJ. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. *Br J Clin Pharmacol* 1994;37:82-85.
139. Wallis SC, Gahan LR, Charles BG et al. Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin: synthesis, X-ray structural characterization, and potentiometric study. *J Inorg Biochem* 1996;62:1-16.
140. Balfour JA, Wiseman LR. Moxifloxacin. *Drugs* 1999;57:363-373; discussion 374.
141. Li RC, Lo KN, Lam JS, Lau PY. Effects of order of magnesium exposure on the postantibiotic effect and bactericidal activity of ciprofloxacin. *J Chemother* 1999;11:243-247.
142. Sirtori CR, Barbi S, Dorigotti F et al. Iron-ovotransferrin preparation does not interfere with fluoroquinolone absorption. *Therapie* 1995;50(Suppl):Abstract 500.
143. Pazzucconi F, Barbi S, Baldassarre D et al. Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption. *Clin Pharmacol Ther* 1996;59:418-422.
144. Wong PY, Zhu M, Li RC. Pharmacokinetic and pharmacodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. *J Chemother* 2000;12:286-293.
145. LePennec MP, Kitzis MD, Terdjman M et al. Possible interaction of ciprofloxacin with ferrous sulphate. *J Antimicrob Chemother* 1990;25:184-185.
146. Lode H, Stuhler P, Deppermann KH et al. Pharmacokinetic interactions between oral ciprofloxacin (CIP)/ofloxacin (OFL) and ferro-salts. *Intersci Conf Antimicrob Agents Chemother* 1989;29:136.
147. Brouwers JR, Van der Kam HJ, Sijtsma J, Proost JH. Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate. *Pharm Weekbl Sci* 1990;12:182-183.

Citations and Reference Literature: Iron

148. Sorgel F, Naber KG, Kinzig M et al. Effect of ferrous sulfate on fleroxacin analyzed by the confidence interval (CI) approach. *Pharm Res* 1995;12(9 Suppl):S-422.
149. Shiba K, Kusajima H, Momo K. The effects of aluminum hydroxide, cimetidine, ferrous sulfate, green tea and milk on pharmacokinetics of gatifloxacin in healthy humans. *J Antimicrob Chemother* 1999;44(Suppl A):141.
150. Allen A, Bygate E, Faessel H et al. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. *Int J Antimicrob Agents* 2000;15:283-289.
151. Shiba K, Okazaki O, Aoki H et al. Inhibition of DR-3355 absorption by metal ions. *Intersci Conf Antimicrob Agents Chemother* 1991;31:198.
152. Lehto P, Kivistö KT. Different effects of products containing metal ions on the absorption of lomefloxacin. *Clin Pharmacol Ther* 1994;56:477-482.
153. Campbell NR, Kara M, Hasinoff BB et al. Norfloxacin interaction with antacids and minerals. *Br J Clin Pharmacol* 1992;33:115-116.
154. Kanemitsu K, Hori S, Yanagawa A, Shimada J. Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats. *Drugs* 1995;49 Suppl 2:352-356.
155. Kanemitsu K, Hori S, Yanagawa A, Shimada J. Effect of ferrous sulfate on the pharmacokinetics of sparfloxacin. *Chemotherapy (Japan)* 1994;42:6-13.
156. Martínez Cabarga M, Sánchez Navarro A, Colino Gandarillas CI, Domínguez-Gil A. Effects of two cations on gastrointestinal absorption of ofloxacin. *Antimicrob Agents Chemother* 1991;35:2102-2105.
157. Orrego-Matte H, Fernández O, Mena I. Effect of anticholinergic agents on the intestinal absorption of ⁵⁹Fe ferrous citrate. *Am J Dig Dis* 1971;16:789-795.
158. Bjarnason I, Macpherson AJ. Intestinal toxicity of non-steroidal anti-inflammatory drugs. *Pharmacol Ther* 1994;62:145-157.
159. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. *Dis Colon Rectum* 1995;38:1311-1321.
160. Bertschinger P, Zala GF, Fried M. [Effect of non-steroidal antirheumatic agents on the gastrointestinal tract: clinical aspects and pathophysiology]. *Schweiz Med Wochenschr* 1996;126:1566-1568.
161. Battistella M, Mamdani MM, Juurlink DN et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. *Arch Intern Med* 2005;165:189-192.
162. Giglio MJ, Bozzini CE. Effect of indomethacin on red cell volume, iron kinetics and red cell survival in mice. *Exp Hematol* 1982;10:487-492.
163. Ganchev T, Negrev N, Mileva V. Effects of indomethacin on erythropoiesis and plasma iron in rats. *Acta Physiol Pharmacol Bulg* 1989;15:53-57.
164. Burghuber O. [Aplastic anemia following indomethacin therapy]. *Acta Med Austriaca Suppl* 1979;6:384-386.
165. Schattner A, Shtalrid M, Levy R, Berrebi A. Fatal aplastic anemia due to indomethacin: lymphocyte transformation tests in vitro. *Isr J Med Sci* 1981;17:433-436.
166. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. *JAMA* 1986;256:1749-1757.
167. Troost FJ, Brummer R-JM, Saris WHM. The effect of chronic iron therapy and indomethacin challenge on intestinal permeability in iron deficient women. *Dig Dis Week* 2001; May 20.
168. Troost FJ, Saris WH, Brummer RJ. Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. *Eur J Clin Nutr* 2003;57:1579-1585.
169. Blumberg BS, Lustbader ED, Whitford PL. Changes in serum iron levels due to infection with hepatitis B virus. *Proc Natl Acad Sci USA* 1981;78:3222-3224.
170. Van Thiel DH, Friedlander L, Fagiuoli S et al. Response to interferon alpha therapy is influenced by the iron content of the liver. *J Hepatol* 1994;20:410-415.
171. Fargion S, Fracanzani AL, Sampietro M et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol* 1997;9:497-503.
172. Hayashi H, Takikawa T, Nishimura N et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. *Am J Gastroenterol* 1994;89:986-988.
173. Fong TL, Han SH, Tsai NC et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. *J Hepatol* 1998;28:369-374.
174. Fontana RJ, Israel J, LeClair P et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. *Hepatology* 2000;31:730-736.

Citations and Reference Literature: Iron

175. Di Bisceglie AM, Bonkovsky HL, Chopra S et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. *Hepatology* 2000;32:135-138.
176. Fargion S, Fracanzani AL, Rossini A et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. *Am J Gastroenterol* 2002;97:1204-1210.
177. Tandon N, Thakur V, Guptan RK, Sarin SK. Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease. *Br J Nutr* 2000;83:235-239.
178. Tanaka K, Ikeda M, Nozaki A et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. *Jpn J Cancer Res* 1999;90:367-371.
179. Campbell NR, Hasinoff BB, Stalts H et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. *Ann Intern Med* 1992;117:1010-1013.
180. Beard JL, Borel MJ, Derr J. Impaired thermoregulation and thyroid function in iron-deficiency anemia. *Am J Clin Nutr* 1990;52:813-819.
181. Campbell NR, Wong NC, Hasinoff BB et al. Ferrous sulfate reduces thyroxine efficacy. *Clin Pharmacol Ther* 1992;165.
182. Beard J, Borel M, Peterson FJ. Changes in iron status during weight loss with very-low-energy diets. *Am J Clin Nutr* 1997;66:104-110.
183. Beard JL, Brigham DE, Kelley SK, Green MH. Plasma thyroid hormone kinetics are altered in iron-deficient rats. *J Nutr* 1998;128:1401-1408.
184. Schlienger JL. [Increased need for thyroxine induced by iron sulfate]. *Presse Med* 1994;23:492.
- 184a. Shakir KM, Chute JP, Aprill BS, Lazarus AA. Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. *South Med J* 1997;90(6):637-639.
185. Campbell NR, Campbell RR, Hasinoff BB. Ferrous sulfate reduces methyl dopa absorption: methyl dopa:iron complex formation as a likely mechanism. *Clin Invest Med* 1990;13:329-332.
186. Campbell N, Paddock V, Sundaram R. Alteration of methyl dopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate. *Clin Pharmacol Ther* 1988;43:381-386.
187. Roe DA. *Drug-Induced Nutritional Deficiencies*. 2nd ed. Westport, Conn: Avi Publishing; 1985.
188. Jacobson ED, Chodos RB, Faloon WW. An experimental malabsorption syndrome induced by neomycin. *Am J Med* 1960;28:524-533.
189. Miale JB, Kent JW. The effects of oral contraceptives on the results of laboratory tests. *Am J Obstet Gynecol* 1974;120:264-272.
190. Worthington BS. Nutrition during pregnancy, lactation, and oral contraception. *Nurs Clin North Am* 1979;14:269-283.
191. Webb JL. Nutritional effects of oral contraceptive use: a review. *J Reprod Med* 1980;25:150-156.
192. Tyrer LB. Nutrition and the pill. *J Reprod Med* 1984;29:547-550.
193. Frassinelli-Gunderson EP, Margen S, Brown JR. Iron stores in users of oral contraceptive agents. *Am J Clin Nutr* 1985;41:703-712.
194. Palomo I, Grebe G, Valladares G et al. [Hemoglobin, serum iron and transferrin saturation among users of intrauterine devices and oral contraceptive agents]. *Rev Med Chil* 1990;118:506-511.
195. Masse PG, Roberge AG. Long-term effect of low-dose combined steroid contraceptives on body iron status. *Contraception* 1992;46:243-252.
196. Steegers-Theunissen RP, Van Rossum JM, Steegers EA et al. Sub-50 oral contraceptives affect folate kinetics. *Gynecol Obstet Invest* 1993;36:230-233.
197. Mooij PN, Thomas CM, Doesburg WH, Eskes TK. The effects of oral contraceptives and multivitamin supplementation on serum ferritin and hematological parameters. *Int J Clin Pharmacol Ther Toxicol* 1992;30:57-62.
198. Jensen JT, Speroff L. Health benefits of oral contraceptives. *Obstet Gynecol Clin North Am* 2000;27:705-721.
199. Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. *Semin Reprod Med* 2001;19:295-303.
200. Miscellaneous products, Penicillamine. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St Louis: Facts and Comparisons; August 1996:714-716b.
201. Osman MA, Patel RB, Schuna A et al. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. *Clin Pharmacol Ther* 1983;33:465-470.
202. Harkness JA, Blake DR. Penicillamine nephropathy and iron. *Lancet* 1982;2:1368-1369.
203. Dukes GE Jr, Duncan BS. *Inflammatory bowel disease. Applied Therapeutics: the Clinical Use of Drugs*. 6th ed. Vancouver, Wash: Applied Therapeutics; 1995:24-27.
204. Neuvonen PJ. Interactions with the absorption of tetracyclines. *Drugs* 1976;11:45-54.

Citations and Reference Literature: Iron

205. Machado FC, Demicheli C, Garnier-Suillerot A, Beraldo H. Metal complexes of anhydrotetracycline. 2. Absorption and circular dichroism study of Mg(II), Al(III), and Fe(III) complexes: possible influence of the Mg(II) complex on the toxic side effects of tetracycline. *J Inorg Biochem* 1995;60:163-173.
206. Howitz PF. The effect of Apurin (allopurinol) on liver function and serum iron. *Dan Med Bull* 1970;17:203-205.
207. Houze P, Rouach H, Gentil M et al. Effect of allopurinol on the hepatic and cerebellar iron, selenium, zinc and copper status following acute ethanol administration to rats. *Free Radic Res Commun* 1991;12-13 Pt 2:663-668.
208. Minerals. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St Louis: Facts and Comparisons; 2000:27-51.
209. Hendler SS, Rorvik DR. *PDR for Nutritional Supplements*. Montvale, NJ: Medical Economics Company; 2001.
210. Powers RH, Stadnicka A, Kalbfleish JH, Skibba JL. Involvement of xanthine oxidase in oxidative stress and iron release during hyperthermic rat liver perfusion. *Cancer Res* 1992;52:1699-1703.
211. Konofal E, Lecendreux M, Arnulf I, Mouren MC. Iron deficiency in children with attention-deficit/hyperactivity disorder. *Arch Pediatr Adolesc Med* 2004;158:1113-1115.
212. De la Cruz JP, Garcia PJ, Sanchez de la Cuesta F. Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals. *Thromb Res* 1992;66:277-285.
213. Central nervous system drugs, Antipsychotic agents. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St Louis: Facts and Comparisons; May 1998:266k-266m.
214. Ben-Shachar D, Youdim MB. Neuroleptic-induced supersensitivity and brain iron. I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity. *J Neurochem* 1990;54:1136-1141.
215. Hamilton SF, Campbell NR, Kara M et al. The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis. *J Rheumatol* 2003;30:1948-1950.
216. Verhoef H, West CE, Nzyuko SM et al. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. *Lancet* 2002;360:908-914.
217. Desai MR, Mei JV, Kariuki SK et al. Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anemia in western Kenya. *J Infect Dis* 2003;187:658-666.
218. Desai MR, Dhar R, Rosen DH et al. Daily iron supplementation is more efficacious than twice weekly iron supplementation for the treatment of childhood anemia in western Kenya. *J Nutr* 2004;134:1167-1174.
219. Taberner DA. Iron deficiency and stanozol therapy. *Lancet* 1983;1:648.
220. Pinto JT. The pharmacokinetic and pharmacodynamic interactions of foods and drugs. *Top Clin Nutr* 1991;6:14-33.
221. Dawson-Hughes B, Seligson FH, Hughes VA. Effects of calcium carbonate and hydroxyapatite on zinc and iron retention in postmenopausal women. *Am J Clin Nutr* 1986;44:83-88.
222. Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. *Am J Clin Nutr* 1991;53:106-111.
223. Hallberg L, Brune M, Erlandsson M et al. Calcium: effect of different amounts on nonheme- and heme-iron absorption in humans. *Am J Clin Nutr* 1991;53:112-119.
224. Hallberg L, Rossander-Hulten L, Brune M, Gleerup A. Inhibition of haem-iron absorption in man by calcium. *Br J Nutr* 1992;53:533-540.
225. Hallberg L, Rossander-Hulten L, Brune M, Gleerup A. Calcium and iron absorption: mechanism of action and nutritional importance. *Eur J Clin Nutr* 1992;46:317-327.
226. Hallberg L. Does calcium interfere with iron absorption? *Am J Clin Nutr* 1998;68:3-4.
227. Sokoll LJ, Dawson-Hughes B. Calcium supplementation and plasma ferritin concentrations in premenopausal women. *Am J Clin Nutr* 1992;56:1045-1048.
228. Lynch SR. Interaction of iron with other nutrients. *Nutr Rev* 1997;55:102-110.
229. Panel on Dietary Antioxidants and Related Compounds, Food and Nutrition Board, Institute of Medicine. *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. Washington, DC: National Academy Press; 2001:290-293.
230. Thompson JR, Gerald PF, Willoughby ML, Armstrong BK. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study. *Lancet* 2001;358:1935-1940.
231. Davis CD, Malecki EA, Greger JL. Interactions among dietary manganese, heme iron, and nonheme iron in women. *Am J Clin Nutr* 1992;56:926-932.
232. Finley JW. Manganese absorption and retention by young women is associated with serum ferritin concentration. *Am J Clin Nutr* 1999;70:37-43.
233. Freeland-Graves JH. Manganese: an essential nutrient for humans. *Nutr Today* 1989;23:10-13.

Citations and Reference Literature: Iron

234. Sirdah MM, El-Agouza IM, Abu Shahla AN. Possible ameliorative effect of taurine in the treatment of iron-deficiency anaemia in female university students of Gaza, Palestine. *Eur J Haematol* 2002;69:236-242.
235. Semba RD, Muhilal, West KPJ et al. Impact of vitamin A supplementation on hematological indicators of iron metabolism and protein status in children. *Nutr Res* 1992;12:469-478.
236. Suharno D, West CE, Muhilal et al. Supplementation with vitamin A and iron for nutritional anaemia in pregnant women in West Java, Indonesia. *Lancet* 1993;342:1325-1328.
237. Muñoz EC, Rosado JL, Lopez P et al. Iron and zinc supplementation improves indicators of vitamin A status of Mexican preschoolers. *Am J Clin Nutr* 2000;71:789-794.
- 237a. Zadik Z, Sinai T, Zung A, Reifen R. Vitamin A and iron supplementation is as efficient as hormonal therapy in constitutionally delayed children. *Clin Endocrinol (Oxf)* 2004;60(6):682-687
238. Brise H, Hallberg L. Effect of ascorbic acid on iron absorption. *Acta Med Scand* 1962;171(Suppl 376):51-58.
239. Lynch SR, Cook JD. Interaction of vitamin C and iron. *Ann NY Acad Sci* 1980;355:32-44.
240. Hallberg L, Brune M, Rossander L. Effect of ascorbic acid on iron absorption from different types of meals: studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. *Hum Nutr Appl Nutr* 1986;40:97-113.
241. Hallberg L, Brune M, Rossander L. The role of vitamin C in iron absorption. *Int J Vitam Nutr Res Suppl* 1989;30:103-108.
242. Hallberg L, Brune M, Rossander L. Iron absorption in man: ascorbic acid and dose-dependent inhibition by phytate. *Am J Clin Nutr* 1989;49:140-144.
243. Hunt JR, Gallagher SK, Johnson LK. Effect of ascorbic acid on apparent iron absorption by women with low iron stores. *Am J Clin Nutr* 1994;59:1381-1385.
244. Siegenberg D, Baynes RD, Bothwell TH et al. Ascorbic acid prevents the dose-dependent inhibitory effects of polyphenols and phytates on nonheme-iron absorption. *Am J Clin Nutr* 1991;53:537-541.
245. Hoffman KE, Yanelli K, Bridges KR. Ascorbic acid and iron metabolism: alterations in lysosomal function. *Am J Clin Nutr* 1991;54:1188S-1192S.
246. Melhorn DK, Gross S. Relationships between iron-dextran and vitamin E in iron deficiency anemia in children. *J Lab Clin Med* 1969;74:789-802.
247. Zago MP, Oteiza PI. The antioxidant properties of zinc: interactions with iron and antioxidants. *Free Radic Biol Med* 2001;31:266-274.
248. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. *Br J Nutr* 1999;81:289-295.
249. Morck TA, Lynch SR, Cook JD. Inhibition of food iron absorption by coffee. *Am J Clin Nutr* 1983;37:416-420.
250. Muñoz LM, Lonnerdal B, Keen CL, Dewey KG. Coffee consumption as a factor in iron deficiency anemia among pregnant women and their infants in Costa Rica. *Am J Clin Nutr* 1988;48:645-651.
251. Merhav H, Amitai Y, Palti H, Godfrey S. Tea drinking and microcytic anemia in infants. *Am J Clin Nutr* 1985;41(6):1210-1213.
252. Koren G, Boichis H, Keren G. Effects of tea on the absorption of pharmacological doses of an oral iron preparation. *Sci Meet Israel* 1982;18:547.
253. Samman S, Sandstrom B, Toft MB et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. *Am J Clin Nutr* 2001;73:607-612.

Reference Literature

- [No authors listed.] *Infect Dis News* June;1990:17.
- [No authors listed.] Iron deficiency: United States, 1999-2000. *MMWR Morb Mortal Wkly Rep* 2002;51(40):897-899.
- [No authors listed.] Product information: Actonel, risedronate. Cincinnati: Procter & Gamble Pharmaceuticals, Inc;1998.
- [No authors listed.] Product information: Prilosec, omeprazole. Wayne, PA: Astra Merck Inc;1995.
- [No authors listed.] Product information: Skelid, tiludronate. New York: Sanofi Pharmaceuticals, Inc;1998.
- [No authors listed.] Product information: Syprine, trientine hydrochloride. West Point, PA: Merck & Co, Inc;1997.
- [No authors listed.] The Food and Nutrition Information Center: National Agricultural Library (NAL), United States Department of Agriculture's (USDA) Agricultural Research Service (ARS). Available at www.nal.usda.gov/fnic/Dietary/rda.html. Accessed March 18, 1999.
- Ahluwalia N, Sun J, Krause D, et al. Immune function is impaired in iron-deficient, homebound, older women. *Am J Clin Nutr* 2004;79(3):516-521.

Citations and Reference Literature: Iron

- Allen J, Backstrom KR, Cooper JA, et al. Measurement of soluble transferrin receptor in serum of healthy adults. *Clin Chem* 1998;44(1): 35-39.
- Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. *Neurology* 2001;56(2): 263-265.
- Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. *Mutat Res* 2001;475(1-2):7-20. (Review)
- Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. *Am J Clin Nutr* 2002;75(4):616-658. (Review)
- Anderson GJ, Powell LW. Of metals, mice, and men: what animal models can teach us about body iron loading. *J Clin Invest* 2000;105(9):1185-1186.
- Arvidsson B, Ekenved G, Rybo G, et al. Iron prophylaxis in menorrhagia. *Acta Obstet Gynecol Scand* 1981;60(2):157-160.
- Atamna H. Heme, iron, and the mitochondrial decay of ageing. *Ageing Res Rev* 2004;3(3):303-318.
- Atamna H, Frey WH II. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. *Proc Natl Acad Sci U S A* 2004;101(30):11153-11158.
- Atamna H, Killilea DW, Killilea AN, et al. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. *Proc Natl Acad Sci U S A* 2002;99(23):14807-14812.
- Atamna H, Walter PB, Ames BN. The role of heme and iron-sulfur clusters in mitochondrial biogenesis, maintenance, and decay with age. *Arch Biochem Biophys* 2002;397(2):345-353. (Review)
- Bastani B, Jain A, Pandurangan G. Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. *Nephrology (Carlton)* 2003;8(1):8-10.
- Basu TK, Donaldson D. Intestinal absorption in health and disease: micronutrients. *Best Pract Res Clin Gastroenterol* 2003;17(6): 957-979.
- Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. *Pediatr Clin North Am* 1999;46(5): 977-992.
- Baynes RD, Macfarlane BJ, Bothwell TH, et al. The promotive effect of soy sauce on iron absorption in human subjects. *Eur J Clin Nutr* 1990;44:419-424.
- Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. *Drug Saf* 1998;19(5):355-371. (Review)
- Beard JL. Effectiveness and strategies of iron supplementation during pregnancy. *Am J Clin Nutr* 2000;71(Suppl):1288S-1294S. (Review)
- Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. *J Nutr* 2001;131(2S-2):568S-579S. (Review)
- Beard JL, Dawson HD. Iron. In: O'Dell BL, Sunde RA, eds. *Handbook of nutritionally essential minerals*. New York: Marcel Dekker, Inc; 1997:275-334.
- Belton N. Iron deficiency in infants and young children. *Professional Care Mother Child* 1995;5:69-71.
- Bender-Gotze C. Therapy of juvenile iron deficiency with bivalent iron dragees (Fe2-fumarate, succinate, sulfate): controlled double-blind study. *Fortschr Med* 1980;98:590-593. [German]
- Bendich A, Cohen M. Ascorbic acid safety: analysis of factors affecting iron absorption. *Toxicol Lett* 1990;51:189-201.
- Bergmann RL, Gravens-Muller L, Hertwig K, et al. Iron deficiency is prevalent in a sample of pregnant women at delivery in Germany. *Eur J Obstet Gynecol Reprod Biol* 2002;102(2):155-160.
- Bezwoda WR, Torrance JD, Bothwell TH, et al. Iron absorption from red and white wines. *Scand J Haematol* 1985;34:121-127.
- Bhatia MS, Singhal PK, Dhar NK, et al. Breath holding spells: an analysis of 50 cases. *Indian Pediatr* 1990;27:1073-1079.
- Bienfait HF, Van Del Briel ML. Rapid mobilization of ferritin iron by ascorbate in the presence of oxygen. *Biochim Biophys Acta* 1980;631:507-510.
- Bjorn-Rasmussen E, Hallberg L. Effect of animal proteins on the absorption of food iron in man. *Nutr Metab* 1979;23:192-202.
- Blank HM, Cogswell ME, Gillespie C, et al. Iron supplement use and iron status among US adults: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2005;82:1024-1031.
- Bostick R. Diet and nutrition in the prevention of colon cancer. In: Bendich A, Deckelbaum RJ, eds. *Preventive nutrition: the comprehensive guide for health professionals*. 2nd ed. Totowa: Humana Press, Inc; 2001:57-95.
- Bothwell TH. Iron in the soul. *Proc R Coll Physicians Edinb* 1991;21(1):72-81.
- Bothwell TH, Bradlow BA, Jacobs P, et al. Iron metabolism in scurvy with special reference to erythropoiesis. *Br J Haematol* 1964;10:50-58.
- Bradman A, Eskenazi B, Sutton P, et al. Iron deficiency associated with higher blood lead in children living in contaminated environments. *Environ Health Perspect* 2001;109(10):1079-1084.

Citations and Reference Literature: Iron

- Bridge EM, Livingston S, Tietze C. Breath-holding spells: their relationship to syncope, convulsions and other phenomena. *J Pediatr* 1943;23:539-561.
- Brise H. Influence of meals on iron absorption in oral iron therapy. *Acta Med Scand* 1962;171(Suppl 376):39-45.
- Brody T. Nutritional biochemistry. 2nd ed. San Diego: Academic Press; 1999.
- Brotanek JM, Halterman JS, Auinger P, et al. Iron deficiency, prolonged bottle-feeding, and racial/ethnic disparities in young children. *Arch Pediatr Adolesc Med* 2005;159(11):1038-1042.
- Brutsaert TD, Hernandez-Cordero S, Rivera J, et al. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. *Am J Clin Nutr* 2003;77:441-448.
- Calabrese V, Butterfield DA, Stella AM. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. *Ital J Biochem* 2003;52(4):177-181. (Review)
- Calvo E, Hertrampf E, de Pablo S, et al. Haemoglobin-fortified cereal: an alternative weaning food with high iron bioavailability. *Eur J Clin Nutr* 1989;43:237-243. (Review)
- Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. *Br J Clin Pharmacol* 1991;31(3):251-255. (Review)
- Campbell NR, Paddock V, Sundaram R. Alteration of methyl dopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate. *Clin Pharmacol Ther* 1988;43(4):381-386.
- Canonne-Hergaux F, Gruenheid S, Ponka P, et al. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. *Blood* 1999;93(12):4406-4417.
- Casparis D, Del Carlo P, Branconi F, et al. Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron. *Minerva Ginecol* 1996;48:511-518. [Italian]
- Castaldo A, Tarallo L, Palomba E, et al. Iron deficiency and intestinal malabsorption in HIV disease. *J Pediatr Gastroenterol Nutr* 1996;22:359-363.
- Caulfield LE, Richard SA, Black RE. Undernutrition as an underlying cause of malaria morbidity and mortality in children less than five years old. *Am J Trop Med Hyg* 2004;71(2 Suppl):55-63. (Review)
- Celsing F, Blomstrand E, Werner B, et al. Effects of iron deficiency on endurance and muscle enzyme activity in man. *Med Sci Sports Exerc* 1986;18:156-161.
- Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. *Morbidity and Mortality Wkly Rep* 1998;47(RR-3):1-29.
- Charlton RW, Jacobs P, Seftel H, et al. Effect of alcohol on iron absorption. *Br Med J* 1964;5422:1427-1429.
- Chavarro JE, Rich-Edwards JW, Rosner BA, et al. Iron intake and risk of ovulatory infertility. *Obstet Gynecol* 2006;108(5):1145-1152.
- Chen WT, Lin YF, Yu FC, et al. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. *Am J Kidney Dis* 2003;42(1):158-166.
- Chiang WC, Tsai TJ, Chen YM, et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. *Clin Nephrol* 2002;58(5):363-369.
- Chin TF, Lach JL. Drug diffusion and bioavailability: tetracycline metallic chelation. *Am J Hosp Pharm* 1975;32(6):625-629.
- Christen Y. Oxidative stress and Alzheimer disease. *Am J Clin Nutr* 2000;71(Suppl):621S-629S.
- Christian P, Khatry SK, Katz J, et al. Effects of alternative maternal micronutrient supplements on low birth weight in rural Nepal: double blind randomised community trial. *BMJ* 2003;326(7389):571.
- Chuang CL, Liu RS, Wei YH, et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. *Nephrol Dial Transplant* 2003;18(2):370-377.
- Cogswell ME, Kettel-Khan L, Ramakrishnan U. Iron supplement use among women in the United States: science, policy and practice. *J Nutr* 2003;133(6):1974S-1977S.
- Cogswell ME, Parvanta I, Ickes L, et al. Iron supplementation during pregnancy, anemia, and birth weight: a randomized controlled trial. *Am J Clin Nutr* 2003;78(4):773-781.
- Colina KF, Abelson HT. Resolution of breath-holding spells with treatment of concomitant anemia. *J Pediatr* 1995;126:395-397.
- Cook JD. Iron-deficiency anaemia. *Baillieres Clin Haematol* 1994;7(4):787-804. (Review)
- Cook JD, Monsen ER. Food iron absorption in human subjects:III: comparison of the effect of animal proteins on nonheme iron absorption. *Am J Clin Nutr* 1976;29:859-867.
- Cook JD, Morck TA, Lynch SR. The inhibitory effect of soy products on nonheme iron absorption in man. *Am J Clin Nutr* 1981;34:2622-2629.
- Cook JD, Reddy MB, Hurrell RF. The effect of red and white wines on nonheme-iron absorption in humans. *Am J Clin Nutr* 1995;61:800-804.

Citations and Reference Literature: Iron

- Dallman PR. Manifestations of iron deficiency. *Semin Hematol* 1982;19(1):19-30. (Review)
- Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. *Circulation* 1999;99:852-854.
- Daoud AS, Batieha A, Abu-Ekteish F, et al. Iron status: a possible risk factor for the first febrile seizure. *Epilepsia* 2002;43(7):740-743.
- Daoud AS, Batieha A, al-Sheyyab M, et al. Effectiveness of iron therapy on breath-holding spells. *J Pediatr* 1997;130(4):547-550.
- D'Arcy PF, McElnay JC. Drug interactions in the gut involving metal ions. *Rev Drug Metabol Drug Interact* 1985;5(2-3):83.
- D'Souza RF, Feakins R, Mears L, et al. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2005;21(5):519-524.
- Das KM, Eastwood MA. Effect of iron and calcium on salicylazosulphapyridine metabolism. *Scand Med J* 1973;18:45-50.
- Davolos A, Castillo J, Marrugat J, et al. Body iron stores and early neurologic deterioration in acute cerebral infarction. *Neurology* 2000;54:1568-1574.
- Davidsson L, Kastenmayer P, Szajewska H, et al. Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate. *Am J Clin Nutr* 2000;71:1597-1602.
- Davila-Hicks P, Theil EC, Lonnerdal B. Iron in ferritin or in salts (ferrous sulfate) is equally bioavailable in nonanemic women. *Am J Clin Nutr* 2004;80:936-940.
- Day SM, Duquaine D, Mundada LV, et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. *Circulation* 2003;107:2601-2606.
- De Block CE, Van Campenhout CM, De Leeuw IH, et al. Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. *Diabetes Care* 2000;23(9):1384-1388.
- de Valk B, Marx MMJ. Iron, atherosclerosis, and ischemic heart disease. *Arch Intern Med* 1999;159:1542-1548. (Review)
- Deira J, Diego J, Martinez R, et al. Comparative study of intravenous ascorbic acid versus low-dose desferrioxamine in patients on hemodialysis with hyperferritinemia. *J Nephrol* 2003;16(5):703-709.
- Derman D, Sayers M, Lynch SR, et al. Iron absorption from a cereal-based meal containing cane sugar fortified with ascorbic acid. *Br J Nutr* 1977;38:261-269.
- Dewey KG, Domellof M, Cohen RJ, et al. Iron supplementation affects growth and morbidity of breast-fed infants: results of a randomized trial in Sweden and Honduras. *J Nutr* 2002;132(11):3249-3255.
- Dewey KG, Romero-Abal ME, Quan de Serrano J, et al. A randomized intervention study of the effects of discontinuing coffee intake on growth and morbidity of iron-deficient Guatemalan toddlers. *J Nutr* 1997;127(2):306-313.
- Dietzfelbinger H. Bioavailability of bi- and trivalent oral iron preparations: investigations of iron absorption by postabsorption serum iron concentrations curves. *Arzneimittelforschung* 1987;37:107-112. (Review)
- Dimitriou H, Stiakaki E, Markaki EA, et al. Soluble transferrin receptor levels and soluble transferrin receptor/log ferritin index in the evaluation of erythropoietic status in childhood infections and malignancy. *Acta Paediatr* 2000;89(10):1169-1173.
- Diplock AT. Safety of antioxidant vitamins and beta-carotene. *Am J Clin Nutr* 1995;62(Suppl 6):1510S-1516S.
- Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. *Gut* 1975;16:193-200.
- Domellof M, Dewey KG, Lonnerdal B, et al. The diagnostic criteria for iron deficiency in infants should be reevaluated. *J Nutr* 2002;132(12):3680-3686.
- Domellof M, Lonnerdal B, Abrams SA, et al. Iron absorption in breast-fed infants: effects of age, iron status, iron supplements, and complementary foods. *Am J Clin Nutr* 2002;76(1):198-204.
- Domellof M, Lonnerdal B, Dewey KG, et al. Sex differences in iron status during infancy. *Pediatrics* 2002;110(3):545-552.
- Doyle W. The association between maternal diet and birth dimensions. *J Nutr Med* 1990;1:9-17.
- Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. *Circulation* 2001;103(23):2799-2804.
- Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. *Neurology* 2000;54(8):1698-1700.
- Engle PL, VasDias T, Howard I, et al. Effects of discontinuing coffee intake on iron deficient Guatemalan toddlers' cognitive development and sleep. *Early Hum Dev* 1999;53(3):251-269.
- Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. *Lancet* 2002;360(9343):1347-1360.
- Fairbanks VF. Iron in medicine and nutrition. In: Shils M, Olson JA, Shike M, et al, eds. *Nutrition in health and disease*. 9th ed. Baltimore: Williams & Wilkins; 1999:223-239.
- Farmer JA, Gotto AM Jr. Antihyperlipidaemic agents: drug interactions of clinical significance. *Drug Saf* 1994;11(5):301-309.
- Farmer JA, Gotto AM Jr. Choosing the right lipid-regulating agent: a guide to selection. *Drugs* 1996;52(5):649-661.

Citations and Reference Literature: Iron

- Fernandez-Real JM, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. *Diabetes Care* 2002;25(12):2249-2255.
- Ferrenini E. Insulin resistance, iron, and the liver. *Lancet* 2000;355:2181-2182.(Letter)
- Finch CA, Huebers H. Perspectives in iron metabolism. *N Engl J Med* 1982;306(25):1520-1528. (Review)
- Fischer Walker C, Kordas K, Stoltzfus RJ, et al. Interactive effects of iron and zinc on biochemical and functional outcomes in supplementation trials. *Am J Clin Nutr* 2005;82(1):5-12. (Review)
- Fleming DJ, Jacques PF, Dallal GE, et al. Dietary determinants of iron stores in a free-living elderly population: the Framingham Heart Study. *Am J Clin Nutr* 1998;67:722-733.
- Fleming DJ, Jacques PF, Tucker KL, et al. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. *Am J Clin Nutr* 2001;73(3):638-646.
- Ford PA, Ford JM. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. *Transfusion* 2004;44(12 Suppl): 15S-25S.
- Fox TE, Eagles J, Fairweather-Tait SJ. Bioavailability of iron glycine as a fortificant in infant foods. *Am J Clin Nutr* 1998;67:664-668.
- Freeland-Graves JH. Manganese: an essential nutrient for humans. *Nutr Today* 1989;23:10-13. (Review)
- Freeland-Graves J. Mineral adequacy of vegetarian diets. *Am J Clin Nutr* 1988;48(3 Suppl):859-862. (Review)
- Friedmann B, Weller E, Mairbaurl H, et al. Effects of iron repletion on blood volume and performance capacity in young athletes. *Med Sci Sports Exerc* 2001;33:741-746.
- Friel JK, Andrews WL, Aziz K, et al. A randomized trial of two levels of iron supplementation and developmental outcome in low birth weight infants. *J Pediatr* 2001;139(2):254-260.
- Frykman E, Bystrom M, Jansson U, et al. Side effects of iron supplements in blood donors: superior tolerance of heme iron. *J Lab Clin Med* 1994;123:561-564.
- Galan P, Yoon HC, Preziosi P, et al. Determining factors in the iron status of adult women in the SU.VI.MAX study: SUPplementation en Vitamines et Mineraux AntioXydants. *Eur J Clin Nutr* 1998;52(6):383-388.
- Galloway R, Dusch E, Elder L, et al. Women's perceptions of iron deficiency and anemia prevention and control in eight developing countries. *Soc Sci Med* 2002;55(4):529-544.
- Galloway R, McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? *Soc Sci Med* 1994;39(3):381-390. (Review)
- Gastaldello K, Vereerstraeten A, Nzame-Nze T, et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. *Nephrol Dial Transplant* 1995;10(Suppl 6):44-47.
- Geerligs PD, Brabin BJ, Omari AA. Food prepared in iron cooking pots as an intervention for reducing iron deficiency anaemia in developing countries: a systematic review. *J Hum Nutr Diet* 2003;16(4):275-281.
- Gera T, Sachdev HP. Effect of iron supplementation on incidence of infectious illness in children: systematic review. *BMJ* 2002;325(7373):1142. (Review)
- Giancaspro V, Nuzziello M, Pallotta G, et al. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. *J Nephrol* 2000;13(6):444-449.
- Gibbs MA. Ascorbic acid use in hyporesponders to Epoetin alfa. *Nephrol Nurs J* 2000;27(4):413-415.
- Gibson RS. Strategies for preventing micronutrient deficiencies in developing countries. *Asia Pac J Clin Nutr* 2004;13(Suppl):S23.
- Goldberg A. The enzymic formation of haem by the incorporation of iron into protoporphyrin: importance of ascorbic acid, ergothioneine and glutathione. *Br J Haematol* 1959;5:150-157.
- Gordon N. Iron deficiency and the intellect. *Brain Dev* 2003;25(1):3-8. (Review)
- Graham-McGregor S, Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. *J Nutr* 2001;131(2S-2):649S-666S. (Review)
- Gunnarsson BS, Thorsdottir I, Palsson G. Iron status in 2-year-old Icelandic children and associations with dietary intake and growth. *Eur J Clin Nutr* 2004;58(6):901-906.
- Hallberg L. Bioavailability of dietary iron in man. *Annu Rev Nutr* 1981;1:123-147. (Review)
- Hallberg L. Combating iron deficiency: daily administration of iron is far superior to weekly administration. *Am J Clin Nutr* 1998;68(2): 213-217.
- Hallberg L, Hulthen L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. *Am J Clin Nutr* 2000;71:1147-1160.
- Hallberg L, Rossander L. Effect of different drinks on the absorption of non-heme iron from composite meals. *Hum Nutr Appl Nutr* 1982;36:116-123.
- Hallberg L, Rossander L. Effect of soy protein on nonheme iron absorption in man. *Am J Clin Nutr* 1982;36:514-520.

Citations and Reference Literature: Iron

- Hallberg L, Rossander L. Improvement of iron nutrition in developing countries: comparison of adding meat, soy protein, ascorbic acid, citric acid, and ferrous sulphate on iron absorption from a simple Latin American-type of meal. *Am J Clin Nutr* 1984;39:577-583.
- Hallberg L, Rossander L, Skanberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. *Am J Clin Nutr* 1987;45(5):988-996.
- Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. *Pediatrics* 2001;107(6):1381-1386.
- Hansen CM. Oral iron supplements. *Am Pharm* 1994;NS34:66-71. (Review)
- Harju E. Clinical pharmacokinetics of iron preparations. *Clin Pharmacokinet* 1989;17:69-89. (Review)
- Harvey LJ, Dainty JR, Hollands WJ, et al. Effect of high-dose iron supplements on fractional zinc absorption and status in pregnant women. *Am J Clin Nutr* 2007;85(1):131-136.
- Haschke F, Ziegler EE, Edwards BB, et al. Effect of iron fortification of infant formula on trace mineral absorption. *J Pediatr Gastroenterol Nutr* 1986;5:768-773.
- Hathcock JN. Metabolic mechanisms of drug-nutrient interactions. *Fed Proc* 1985;44(1 Pt 1):124-129. (Review)
- Heinrich HC, Oppitz KH, Gabbe EE. Inhibition of iron absorption in man by tetracycline. *Klin Wochenschr* 1974;52:493-498. [German]
- Hendler SS, Rorvik DR, eds. *PDR for nutritional supplements*. Montvale, NJ: Medical Economics Company, Inc; 2001.
- Herberg S, Preziosi P, Galan P. Iron deficiency in Europe. *Public Health Nutr* 2001;4(2B):537-545.
- Hertrampf E, Olivares M, Pizarro F, et al. Haemoglobin fortified cereal: a source of available iron to breast-fed infants. *Eur J Clin Nutr* 1990;44:793-798.
- Hines Burnham T, et al, eds. *Drug facts and comparisons*. St Louis: Facts and Comparisons; 2000:1294.
- Hinton PS, Giordano C, Brownlie T, et al. Iron supplementation improves endurance after training in iron depleted, nonanemic women. *J Appl Physiol* 2000;88(3):1103-1111.
- Hoffbrand AV, Wonke B. Iron chelation therapy. *J Intern Med Suppl* 1997;740:37-41.
- Hoffbrand AV. Prospects for oral iron chelation therapy. *J Lab Clin Med* 1994;123(4):492-494. (Review)
- Holowach J, Thurston DL. Breath-holding spells and anemia. *N Engl J Med* 1963;268:21-23.
- Holt GA. *Food and drug interactions*. Chicago: Precept Press;1998. (Review)
- Hua NW, Stoohs RA, Facchini FS. Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. *Br J Nutr* 2001;86(4):515-519.
- Hurrell RF, Furniss DE, Burri J, et al. Iron fortification of infant cereals: a proposal for the use of ferrous fumarate or ferrous succinate. *Am J Clin Nutr* 1989;49:1274-1282.
- Hurtado EK, Claussen AH, Scott KG. Early childhood anemia and mild or moderate mental retardation. *Am J Clin Nutr* 1999;69:115-119.
- Hussain MA, Green N, Flynn DM, et al. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. *Lancet* 1977;1(8019):977-979.
- Iannotti LL, Tielsch JM, Black MM, et al. Iron supplementation in early childhood: health benefits and risks. *Am J Clin Nutr* 2006;84(6):1261-1276. (Review)
- Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin B6 in genetically-confirmed Alzheimer's disease. *Lancet* 1992;340(8820):671.
- Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. *Science* 2001;292(5516):464-468.
- Iwasa M, Iwata K, Kaito M, et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. *Nutrition* 2004;20(4):368-371.
- Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. *Science* 2001;292(5516):468-472.
- Jiang R, Ma J, Ascherio A, et al. Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. *Am J Clin Nutr* 2004;79(1):70-75.
- Kahn JL, Binns HJ, Chen T, et al. Persistence and emergence of anemia in children during participation in the Special Supplemental Nutrition Program for Women, Infants, and Children. *Arch Pediatr Adolesc Med* 2002;156(10):1028-1032.
- Kaltwasser JP, Werner E, Schalk K, et al. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. *Gut* 1998;43:699-704.
- Kato I, Dnistrian AM, Schwartz M, et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. *Int J Cancer* 1999;80(5):693-698.

Citations and Reference Literature: Iron

- Keven K, Kutlay S, Nergizoglu G, et al. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. *Am J Kidney Dis* 2003;41(6):1233-1239.
- Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. *Circulation* 1997;96(10):3300-3307.
- Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. *Cell* 1993;72(1):19-28. (Review)
- Klingshirn LA, Pate RR, Bourque SP, et al. Effect of iron supplementation on endurance capacity in iron-depleted female runners. *Med Sci Sports Exerc* 1992;24:819-824.
- Klipstein-Grobusch K, Grobbee DE, den Breeijen JH, et al. Dietary iron and risk of myocardial infarction in the Rotterdam Study. *Am J Epidemiol* 1999;149(5):421-428.
- Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. *Am J Clin Nutr* 1999;69:1231-1236.
- Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. *Med Toxicol* 1987;2(1):10-32.
- Kohgo Y, Torimoto Y, Kato J. Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor. *Int J Hematol* 2002;76(3):213-218.
- Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. *Aliment Pharmacol Ther* 1992;6(4):399-406. (Review)
- Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. *J Clin Gastroenterol* 1992;14(4):288-292.
- Kosch M, Schaefer RM. Iron management in renal failure patients: how do we achieve the best results? *EDTNA ERCA J* 2002;28:182-184.
- Krezenlok EP, Hoff JV. Accidental iron poisoning: a problem of marketing and labeling. *Pediatrics* 1979;63:591-596.
- LaManca JJ, Haymes EM. Effects of iron repletion on VO₂max, endurance, and blood lactate in women. *Med Sci Sports Exerc* 1993;25:1386-1392.
- Lao TT, Tam K, Chan LY. Third trimester iron status and pregnancy outcome in non-anaemic women; pregnancy unfavourably affected by maternal iron excess. *Hum Reprod* 2000;15:1843-1848.
- Layrisse M, Martinez-Torres C, Roche M. Effect of interaction of various foods on iron absorption. *Am J Clin Nutr* 1968;21:1175-1183.
- Lee DH, Anderson KE, Harnack LJ, et al. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. *J Natl Cancer Inst* 2004;96(5):403-407.
- Lee GR. Disorders of iron metabolism and heme synthesis. In: Lee GR, Foerster J, Paraskevas F, et al, eds. *Wintrobe's clinical hematology*. 10th ed. Baltimore: Williams and Wilkins; 1999:979-1070.
- Leng S, Chaves P, Koenig K, et al. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. *J Am Geriatr Soc* 2002;50(7):1268-1271.
- Leonards JR, Levy G, Niemczura R. Gastrointestinal blood loss during prolonged aspirin administration. *N Engl J Med*. 1973;289(19):1020-1022.
- Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride: effect of food, milk, and iron. *J Am Acad Dermatol* 1985;12(2 Pt 1):308-312.
- Li CL, Werner P, Cohen G. Lipid peroxidation in brain: interactions of L-DOPA/dopamine with ascorbate and iron. *Neurodegeneration* 1995;4(2):147-153. Erratum in *Neurodegeneration* 1995;4(3):347.
- Liehr JG, Jones JS. Role of iron in estrogen-induced cancer. *Curr Med Chem* 2001;8(7):839-849.
- Lih-Brody L, Powell Sr, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. *Dig Dis Sci* 1996;41(10):2078-2086.
- Lim, D, McKay, M. Food-drug interactions. *Drug Information Bull* 1995;15(2). (Review)
- Lin CL, Hsu PY, Yang HY, et al. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. *Ren Fail* 2003;25(3):445-453.
- Lin YW, Okazaki S, Hamahata K, et al. Acute pure red cell aplasia associated with allopurinol therapy. *Am J Hematol* 1999;61(3):209-211.
- Lind T, Hernell O, Lonnerdal B, et al. Dietary iron intake is positively associated with hemoglobin concentration during infancy but not during the second year of life. *J Nutr* 2004;134(5):1064-1070.
- Lochhead AC, Goldberg A. Transfer of iron to protoporphyrin for haem biosynthesis: role of ascorbic acid and glutathione. *Lancet* 1959;2:271-272.

Citations and Reference Literature: Iron

- Logan EC, Yates JM, Stewart RM, et al. Investigation and management of iron deficiency anaemia in general practice: a cluster randomised controlled trial of a simple management prompt. *Postgrad Med J* 2002;78(923):533-537.
- Lönnerdal B, Bryant A. Absorption of iron from recombinant human lactoferrin in young US women. *Am J Clin Nutr* 2006;83:305-309.
- Lozoff B, De Andraca I, Castillo M, et al. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. *Pediatrics* 2003;112(4):846-854. Erratum in *Pediatrics* 2004;113(6):1853.
- Lukaski HC, Bolonchuk WW, Klevay LM, et al. Interactions among dietary fat, mineral status, and performance of endurance athletes: a case study. *Int J Sport Nutr Exerc Metab* 2001;11(2):186-198.
- Lyle WH. Penicillamine and iron. *Lancet* 1976;2(7982):420. (Letter)
- Lynch SR. Interaction of iron with other nutrients. *Nutr Rev* 1997;55(4):102-110. (Review)
- Macfarlane BJ, van der Riet WB, Bothwell TH, et al. Effect of traditional oriental soy products on iron absorption. *Am J Clin Nutr* 1990;51:873-880.
- Mainous AG III, Gill JM, Carek PJ. Elevated serum transferrin saturation and mortality. *Ann Fam Med* 2004;2(2):133-138.
- Mainous AG III, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and risk of cancer. *Ann Fam Med* 2005;3:131-137.
- Mainous AG III, Wells BJ, Koopman RJ, et al. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. *Am J Epidemiol* 2005;161(12):1115-1122.
- Makoff R. Vitamin replacement therapy in renal failure patients. *Miner Electrolyte Metab* 1999;25(4-6):349-351. (Review)
- Marchal C, Spaeth D, Casadevall N, et al. Comité d'organisation des Standards, Options and Recommendations. [Standards, options and recommendations for the use of recombinant erythropoietin (epoietin alpha and beta darbepoietin-alpha, EPO) in the management of anaemia in oncology for patient undergoing radiotherapy-update 2003.] *Cancer Radiother* 2004;8(3):197-206. [French]
- Martin TJ, Grill V. Bisphosphonates: mechanisms of action. *Aust Prescr* 2000;23:130-132. (Review)
- Martinez C, Fox T, Eagles J, et al. Evaluation of iron bioavailability in infant weaning foods fortified with haem concentrate. *J Pediatr Gastroenterol Nutr* 1998;27:419-424.
- Marz R. Medical nutrition from Marz. 2nd ed. Portland, OR: Omni Press; 1997. (Review)
- Maskos Z, Koppenol WH. Oxyradicals and multivitamin tablets. *Free Radic Biol Med* 1991;11:609-610.
- Mason P. Nutrition and dietary advice in the pharmacy. Oxford, UK: Blackwell Scientific; 1994:234-235. (Review)
- Mebratu T, Stoltzfus RJ, Chwaya HM, et al. Low-dose daily iron supplementation for 12 months does not increase the prevalence of malarial infection or density of parasites in young Zanzibari children. *J Nutr* 2004;134(11):3037-3041.
- Menendez C, Schellenberg D, Quinto L, et al. The effects of short-term iron supplementation on iron status in infants in malaria-endemic areas. *Am J Trop Med Hyg* 2004;71(4):434-440.
- Michael B, Coyne DW, Fishbane S, et al. For the Ferrlecit Publication Committee: sodium ferric gluconate complex in hemodialysis patients: adverse reactions when compared to placebo and iron dextran. *Kidney Int* 2002;61:1830-1839.
- Mills KC, Curry SC. Acute iron poisoning. *Emerg Med Clin NorthAm* 1994;12:397-413.
- Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. *Annu Rev Nutr* 2003;23:283-301. (Review)
- Mocan H, Yildiran A, Orhan F, et al. Breath holding spells in 91 children and response to treatment with iron. *Arch Dis Child* 1999;81:261-262.
- Morley R, Abbott R, Fairweather-Tait S, et al. Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial. *Arch Dis Child* 1999;81:247-252.
- Murray-Kolb LE, Beard JL, Joseph LJ, et al. Resistance training affects iron status in older men and women. *Int J Sport Nutr Exerc Metab* 2001;11(3):287-298.
- Murray-Kolb LE, Welch R, Theil EC, et al. Women with low iron stores absorb iron from soybeans. *Am J Clin Nutr* 2003;77(1):180-184.
- Nagral A, Mehta AB, Gomes AT, et al. Serum soluble transferrin receptor in the diagnosis of iron deficiency in chronic liver disease. *Clin Lab Haematol* 1999;21(2):93-97.
- National Heart Lung, and Blood Institute Working Group on Restless Legs Syndrome. Restless legs syndrome: detection and management in primary care. *Am Fam Physician* 2000;62(1):108-114.
- Nead KG, Halterman JS, Kaczorowski JM, et al. Overweight children and adolescents: a risk group for iron deficiency. *Pediatrics* 2004;114(1):104-108.
- Nelson M, Ash R, Mulvihill C, et al. Iron status, diet and cognitive function in British adolescent girls. Poster presented at The Nutrition Society's Nutrition 2000: Research Themes for the New Millennium. Cork, Ireland, Jun 26, 2000.
- Newhouse IJ, Clement DB, Lai C. Effects of iron supplementation and discontinuation on serum copper, zinc, calcium, and magnesium levels in women. *Med Sci Sports Exerc* 1993;25(5):562-571.
- Nightingale SL. Action to prevent accidental iron poisoning in children. *JAMA* 1997;27:1343.

Citations and Reference Literature: Iron

- Nyakeriga AM, Troye-Blomberg M, Dorfman JR, et al. Iron deficiency and malaria among children living on the coast of Kenya. *J Infect Dis* 2004;190(3):439-447.
- O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. *Age Ageing* 1994;23(3):200-203.
- Ogi M, Horiuchi T, Abe R, et al. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients.] *Nippon Jinzo Gakkai Shi* 2004;46(8):804-809. [Japanese]
- Oppenheimer SJ. Iron and its relation to immunity and infectious disease. *J Nutr* 2001;131(2S-2):616S-633S.
- Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. *Am J Med* 1993;95(Suppl 5A):48S-52S. (Review)
- Perez EM, Hendricks MK, Beard JL, et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. *J Nutr* 2005;135(4):850-855.
- Peterson DA, Gerrard JM, Rao GH, et al. Inhibition of ferrous iron induced oxidation of arachidonic acid by indomethacin. *Prostaglandins Med* 1979;2(2):97-108.
- Picciano MF. Pregnancy and lactation: physiological adjustments, nutritional requirements and the role of dietary supplements. *J Nutr* 2003;133(6):1997S-2002S. (Review)
- Pietrangelo A. Hemochromatosis 1998: is one gene enough? *J Hepatol* 1998;29(3):502-509.
- Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. *N Engl J Med* 2004;350(23):2383-2397. (Review)
- Pineda O, Ashmead HD, Perez JM, et al. Effectiveness of iron amino acid chelate on the treatment of iron deficiency anemia in adolescents. *J Appl Nutr* 1994;46:2-13.
- Pinto JT. The pharmacokinetic and pharmacodynamic interactions of foods and drugs. *Top Clin Nutr* 1991;6(3):14-33. (Review)
- Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is common in men with essential hypertension. *J Hypertens* 2002;20(8):1513-1518.
- Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. *Am J Med* 1989;87(5A):76S-81S. (Review)
- Pollitt E. Poverty and child development: relevance of research in developing countries to the United States. *Child Dev* 1994;65(2 Spec No.):283-295.
- Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. *Blood* 1997;89(1):1-25. (Review)
- Powanda MC, Blackburn BS, Bostian KA, et al. Clofibrate-induced alterations in zinc, iron and copper metabolism. *Biochem Pharmacol* 1978;27(1):125-127.
- Powers KM, Smith-Weller T, Franklin GM, et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. *Neurology* 2003;60(11):1761-1766.
- Ramakrishnan U. Nutrition and low birth weight: from research to practice. *Am J Clin Nutr* 2004;79(1):17-21. (Review)
- Ramakrishnan U, Gonzalez-Cossio T, Neufeld LM, et al. Multiple micronutrient supplementation during pregnancy does not lead to greater infant birth size than does iron-only supplementation: a randomized controlled trial in a semirural community in Mexico. *Am J Clin Nutr* 2003;77(3):720-725.
- Rasmussen K. Is there a causal relationship between iron deficiency or iron-deficiency anemia and weight at birth, length of gestation and perinatal mortality? *J Nutr* 2001;131(2S-2):590S-601S.
- Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta* 1997;1331(1):1-40. (Review)
- Ricketts CD. Iron bioavailability from controlled-release and conventional iron supplements. *J Appl Nutr* 1993;45:13-19.
- Riedel MK, Morgenstern T. [Iron replacement in hemodialysis patients with a normal serum ferritin level.] *Dtsch Med Wochenschr* 2004;129(36):1849-1853. [German]
- Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. *Am J Med* 2005;118(10):1142-1147.
- Roe DA. Drug and nutrient interactions in the elderly diabetic. *Drug Nutr Interact* 1988;5(4):195-203. (Review)
- Roe DA. Drug-induced nutritional deficiencies. 2nd ed. Westport, CT: Avi Publishing;1985. (Review)
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. *Drugs and nutrients: the interactive effects*. New York: Marcel Dekker;1984. (Review)
- Roncagliolo M, Garrido M, Walter T, et al. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. *Am J Clin Nutr* 1998;68:683-690.
- Rossander L, Hallberg L, Bjorn-Rasmussen E. Absorption of iron from breakfast meals. *Am J Clin Nutr* 1979;32:2484-249.
- Rowland TW, Deisroth MB, Green GM, et al. The effect of iron therapy on the exercise capacity of nonanemic iron-deficient adolescent runners. *Am J Dis Child* 1988;142:165-169.

Citations and Reference Literature: Iron

- Rudinskas L, Paton TW, Walker SE. Poor clinical response to enteric-coated iron preparations. *Can Med Assoc J* 1989;141:565-566.
- Sakagami H, Satoh K, Fukuchi K, et al. Effect on an iron-chelator on ascorbate-induced cytotoxicity. *Free Radic Biol Med* 1997;23(2):260-270.
- Salahudeen AK, Fleischmann E, Ahmed A, et al. Anemia and iron target realization in 1998: clinical management of anemia in 1,639 patients on hemodialysis. *ASAIO J* 2001;47(5):511-515.
- Salonen JT, Nyyssönen K, Korpela H, et al. High stored iron levels associated with excess risk of myocardial infarction in western Finnish men. *Circulation* 1992;86(3):803-811.
- Sandberg AS, Brune M, Carlsson NG, et al. Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. *Am J Clin Nutr* 1999;70:240-246.
- Sandstrom B, Davidsson L, Cederblad A, et al. Oral iron, dietary ligands and zinc absorption. *J Nutr* 1985;115(3):411-414.
- Say AE, Gursurer M, Yazicioglu MV, et al. Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia. *Am Heart J* 2002;143(2):257-264.
- Schaefer JP, Tam Y, Hasinoff BB, et al. Ferrous sulphate interacts with captopril. *Br J Clin Pharmacol* 1998;46(4):377-381.
- Schaible UE, Collins HL, Priem F, et al. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. *J Exp Med* 2002;196(11):1507-1513.
- Sempos C, Looker AC, Gillum RE, et al. Serum ferritin and death from all causes of cardiovascular disease: the NHANES II Mortality Study. *Ann Epidemiol* 2000;10(7):441-448.
- Seo JK, Ko JS, Choi KD. Serum ferritin and *Helicobacter pylori* infection in children: a sero-epidemiologic study in Korea. *J Gastroenterol Hepatol* 2002;17(7):754-757.
- Sever Y, Ashkenazi A, Tyano S, et al. Iron treatment in children with attention deficit hyperactivity disorder: a preliminary report. *Neuropsychobiology* 1997;35:178-180.
- Shah BK, Gupta P. Weekly vs daily iron and folic acid supplementation in adolescent Nepalese girls. *Arch Pediatr Adolesc Med* 2002;156(2):131-135.
- Shakir KM, Chute JP, Aprill BS, et al. Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. *South Med J* 1997;90(6):637-639.
- Sherman PM, Macarthur C. Current controversies associated with *Helicobacter pylori* infection in the pediatric population. *Front Biosci* 2001;6:E187-192.
- Shils ME, Olson JA, Shike M, eds. *Modern nutrition in health and disease*. 9th ed. Baltimore: Williams & Wilkins; 1999:210,860,1422,1424,1772.
- Siege-Riz AM, Hartzema AG, Turnbull C, et al. The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: a randomized controlled trial. *Am J Obstet Gynecol* 2006;194(2):512-519.
- Silber MH, Richardson JW. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. *Mayo Clin Proc* 2003;78(1):52-54.
- Simmons WK, Cook JD, Bingham KC, et al. Evaluation of a gastric delivery system for iron supplementation in pregnancy. *Am J Clin Nutr* 1993;58:622-626.
- Simonart T, Boelaert JR, Mosselmans R, et al. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. *Gynecol Oncol* 2002;85(1):95-102.
- Simpson KM, Morris ER, Cook JD. The inhibitory effect of bran on iron absorption. *Am J Clin Nutr* 1981;34:1469-1478.
- Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. *Life Sci* 2001;70(1):49-56.
- Skaar EP, Humayun M, Bae T, et al. Iron-source preference of *Staphylococcus aureus* infections. *Science* 2004;305(5690):1626-1628.
- Smythies J. The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. *NeurotoxicolRes* 1999;1(1):27-39. (Review)
- Spaeth D, Casadevall N, Daouphars M, et al; Standards, Options and Recommendations project. [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology: update 2003.] *Bull Cancer* 2004;91(2):179-188. [French]
- Srigiridhar K, Nair KM. Supplementation with alpha-tocopherol or a combination of alpha-tocopherol and ascorbic acid protects the gastrointestinal tract of iron-deficient rats against iron-induced oxidative damage during iron repletion. *Br J Nutr* 2000;84(2):165-173.
- Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. *Aliment Pharmacol Ther* 1998;12(1):83-98.
- Sturniolo GC, Mestriner C, Lecis PE, et al. Altered plasma and mucosal concentrations of trace elements and antioxidants in active ulcerative colitis. *Scand J Gastroenterol* 1998;33:644-649.

Citations and Reference Literature: Iron

- Sullivan JL. Stored iron and ischemic heart disease. *Circulation* 1992;86:1036. (Editorial)
- Sun ER, Chen CA, Ho G, et al. Iron and the restless legs syndrome. *Sleep* 1998;21:371-377.
- Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. *Nephrol Dial Transplant* 1998;13: 2867-2872.
- Tarng DC, Huang TP, Chen TW. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. *Am J Nephrol* 1997;17(2):158-164.
- Tarng DC, Huang TP, Chen TW, et al. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. *Kidney Int Suppl* 1999;69:S107-S118. (Review)
- Tarng DC, Hung SC, Huang TP. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients. *J Am Soc Nephrol* 2004;15(9):2486-2493.
- Tarng DC, Huang T-P, Wei YH. Erythropoietin and iron: the role of ascorbic acid. *Nephrol Dial Transplant* 2001;16(Suppl 5):35-39. (Review)
- Tarng DC, Wei YH, Huang TP, et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. *Kidney Int* 1999;55:2477-2486.
- Taylor RT, Huskisson EC, Whitehouse GH, et al. Gastric ulceration occurring during indomethacin therapy. *Br Med J* 1968;4(633): 734-737.
- Taymor ML, Sturgis SH, Yahia C. The etiological role of chronic iron deficiency in production of menorrhagia. *JAMA* 1964;187:323-327.
- Threlkeld DS, ed. Hormones, thyroid hormones. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons;1991. (Review)
- Threlkeld DS, ed. Miscellaneous products, penicillamine. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons; 1996. (Review)
- Toth I, Bridges KR: Ascorbic acid enhances ferritin mRNA translation by an IRP/Aconitase switch. *J Biol Chem* 1995;270:19540-19544.
- Troost FJ, Saris WH, Haenen GR, et al. New method to study oxidative damage and antioxidants in the human small bowel: effects of iron application. *Am J Physiol Gastrointest Liver Physiol* 2003;285(2):G354-359.
- Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. *Am Fam Physician* 1991;44(5):1651-1658. (Review)
- Turnlund JR. Copper. In: Shils M, Olson JA, Shike M, et al, eds. *Nutrition in health and disease*. 9th ed. Baltimore: Williams & Wilkins; 1999. (Review)
- Tzonou A, Lagiou P, Trichopoulou A, et al. Dietary iron and coronary heart disease risk: a study from Greece. *Am J Epidemiol* 1998;147(2):161-166.
- USDA: Composition of foods:USDA Handbook #8. Washington DC:ARS, USDA;1976-1986.
- US Food and Drug Administration. FDA Medical Bulletin, US Government Printing Office. Document number 386-942/00002. February 6, 1995.
- Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. *Crit Rev Oncol Hematol* 2003;47(1):1-11.
- van den Broek N. Anaemia and micronutrient deficiencies. *Br Med Bull* 2003;67:149-160. PMID:14711761. (Review)
- van der A DL, Peeters PH, Grobbee DE, et al. Dietary haem iron and coronary heart disease in women. *Eur Heart J* 2005;26(3):257-262.
- van Zyl-Smit R, Halkett JA. Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients. *Nephron* 2002;92(2):316-323.
- Verdon F, Burnand B, Fallab Stubi C-L, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. *BMJ* 2003;326:1124-1127.
- Vernet M, Doyen C. Assessment of iron status with a new fully automated assay for transferrin receptor in human serum. *Clin Chem Lab Med* 2000;38(5):437-442.
- Vulpe CD, Kuo YM, Murphy TL, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. *Nat Genet* 1999;21(2):195-199.
- Walker SE, Paton TW, Cowan DH, et al. Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. *Can Med Assoc J* 1989;141:543-547.
- Wang X, Wiesinger J, Beard J, et al. Thy1 expression in the brain is affected by iron and is decreased in restless legs syndrome. *J Neurol Sci* 2004;220(1-2):59-66.
- Weinreb O, Mandel S, Amit T, et al. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. *J Nutr Biochem* 2004;15(9):506-516.

Citations and Reference Literature: Iron

- Welch KM, Nagesh V, Aurora SK, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? *Headache* 2001;41(7):629-637.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press;1997:57-59,221-222. (Review)
- Willeit J, Kiechl S, Oberhollenzer F, et al. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. *Arterioscler Thromb Vasc Biol* 2000;20(2):529-537.
- Williams J, Wolff A, Daly A, et al. Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study. *BMJ* 1999;318:693-697.
- Wright RO. The role of iron therapy in childhood plumbism. *Curr Opin Pediatr* 1999;11(3):255-258.
- Wurapa RK, Gordeuk VR, Brittenham GM, et al. Primary iron overload in African Americans. *Am J Med* 1996;101(1):9-18.
- Wurzelmann JI, Silver A, Schreinemachers DM, et al. Iron intake and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 1996;5(7):503-507.
- Yeung CK, Glahn RP, Miller DD. Inhibition of iron uptake from iron salts and chelates by divalent metal cations in intestinal epithelial cells. *J Agric Food Chem* 2005;53(1):132-136.
- Yip R, Dallman PR. Iron. In: Ziegler EE, Filer LJ, eds. *Present knowledge in nutrition*. 7th ed. Washington,DC: ILSI Press; 1996:277-292. (Review)
- Yip R. Significance of an abnormally low or high hemoglobin concentration during pregnancy: special consideration of iron nutrition. *Am J Clin Nutr* 2000;72(1 Suppl):272S-279S.
- Young IS, Trouton TG, Torney JJ, et al. Antioxidant status and lipid peroxidation in hereditary haemochromatosis. *Free Radic Biol Med* 1994;16:393-397.
- Zadik Z, Sinai T, Zung A, et al. Vitamin A and iron supplementation is as efficient as hormonal therapy in constitutionally delayed children. *Clin Endocrinol (Oxf)* 2004;60(6):682-687.
- Zhou JR, Erdman JW Jr. Phytic acid in health and disease. *Crit Rev Food Sci Nutr* 1995;35(6):495-508. (Review)
- Zimmermann MB, Molinari L, Staubli-Asobayire F, et al. Serum transferrin receptor and zinc protoporphyrin as indicators of iron status in African children. *Am J Clin Nutr* 2005;81:615-623.